Global Blood Therapeutics (GBT) said Friday that its once-a-day pill for sickle cell disease boosted levels of oxygen-carrying hemoglobin in a little more than half of the patients treated in a Phase 3 clinical trial — results that will allow the company to file soon for accelerated approval for the treatment in the U.S.

Some outside experts, however, cautioned that it’s far from certain whether the results will translate into better health outcomes for patients themselves, even if the clinical trial achieved its main goal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy